Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer

Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression

Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer

Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer

Applications of Chiral Squaramides: From Asymmetric Organocatalysis to Biologically Active Compounds

C₃‐Symmetric Cinchonine‐Squaramide‐Catalyzed Asymmetric Chlorolactonization of Styrene‐Type Carboxylic Acids with 1,3‐Dichloro‐5,5‐dimethylhydantoin: An Efficient Method to Chiral Isochroman‐1‐ones